#USA #Gainesville #iOncologi #Dr. Mona Flores #Paolo Fundarò

iOncologi, Inc. Strengthens Leadership Team

Gainesville, FL – iOncologi, Inc., a pioneering biopharmaceutical firm dedicated to innovating immunotherapies for cancer treatment, has recently appointed two distinguished professionals to its Board of Directors: Dr. Mona Flores and Mr. Paolo Fundarò. The inclusion of these two leaders aims to bolster the company’s mission to advance its groundbreaking immunotherapy technologies.

Expertise to Fuel Innovation

Dr. Edgardo Rodriguez-Lebron, CEO of iOncologi, expressed enthusiasm about their appointment, stating, "Dr. Flores' expertise in AI-driven healthcare and Mr. Fundarò's extensive background in biopharmaceutical investments will serve as invaluable assets as we work towards enhancing our immunotherapy platforms."

Dr. Mona Flores brings a wealth of experience in artificial intelligence within the healthcare landscape. She previously held the role of Global Head of Medical AI at NVIDIA and is recognized for her contributions towards integrating advanced AI technologies in clinical settings. With a blend of medical prowess as a board-certified cardiac surgeon, an MBA in Management Information Systems, and thorough understanding from her time on Wall Street, Dr. Flores stands to influence iOncologi’s adaptability in developing cutting-edge cancer therapies by leveraging AI-driven insights.

On the other hand, Mr. Paolo Fundarò comes with extensive experience in both life sciences investments and company leadership. As the Founder and Managing Partner of XGEN Venture, he is focused on early-stage drug development within the biopharmaceutical sector. His previous position as CEO of Genextra exemplifies his capabilities in steering biotech and medical device companies towards successful commercialization. Mr. Fundarò’s robust global connections within the life sciences community will undoubtedly aid in advancing iOncologi's strategic objectives.

Addressing Cancer Challenges

Stressing the importance of the right leadership in combatting complex tumors, both appointees shared their perspectives. Dr. Flores remarked, "The future of immuno-oncology is intertwined with AI and precision medicine. I’m thrilled to join iOncologi and contribute to our collective mission of crafting transformative therapies that will enhance patient outcomes." Likewise, Mr. Fundarò expressed eagerness, stating, "Joining this innovative biotech dedicated to battling tough cancers is an exciting opportunity. I'm keen to collaborate with a team committed to making significant strides in healthcare."

Dr. Duane A. Mitchell, Co-founder and Chairman of the Board, echoed the sentiments of excitement about the new board members, underscoring that "iOncologi is privileged to have such talent at its helm. Dr. Flores and Mr. Fundarò embody the ideal blend of expertise to propel our vision of cutting-edge immunotherapies for solid tumors."

Looking Ahead

The introductions of Dr. Flores and Mr. Fundarò align seamlessly with iOncologi’s commitment to establishing a world-class leadership team geared towards advancing AI-guided immunotherapies. The company is determined to harness innovative approaches in the fight against cancer, aiming for a future where improved patient outcomes are achievable through next-generation cancer treatments.

As iOncologi moves forward, it remains resolute in its mission to leverage the power of the immune system and innovative strategies to reinterpret cancer care in the landscape of biopharmaceutical advancements. For further details on iOncologi and its pioneering projects, please visit www.ioncologi.com.